SK Biopharm Holds '2025 Plan of Action' Meeting

Over 130 Executives and Employees from Headquarters and U.S. Subsidiary Participate

SK Biopharm announced on October 2 that its U.S. subsidiary, SK Life Science, held the '2025 Plan of Action (POA)' meeting in Chicago, Illinois, USA, from September 29 to October 1 (local time).

Participants of the '2025 Plan of Action (POA)' held by SK Life Sciences, the U.S. subsidiary of SK Biopharm, in Chicago, Illinois, USA, from the 29th of last month to the 1st (local time), are taking a commemorative photo. SK Biopharm

The POA meeting is an event where field staff from the U.S. pharmaceutical and biotech company gather to share achievements and boost motivation. Since the launch of cenobamate in 2020, SK Life Science has held the POA meeting every fall, establishing it as an annual event to enhance sales capabilities, alongside the National Sales Meeting held at the beginning of the year.

This year marked the sixth edition of the event, with more than 130 executives and employees from SK Biopharm and SK Life Science in attendance. The meeting celebrated record-high sales in the first half of the year and the achievement of 170,000 cumulative prescribed patients, and discussed strategies to further expand performance in the second half. SK Biopharm CEO Lee Donghun shared key strategies for the second half of the year during his on-site presentation, including new modalities such as radiopharmaceuticals (RPT), targeted protein degradation (TPD), and plans to introduce a second commercialized product.

Notably, this year's event included not only sales staff but also members from headquarters, who joined to strengthen organizational cohesion and broaden their understanding of strategic direction through direct exchanges with the U.S. subsidiary.

During the CEO presentation on September 30, Lee stated, "SK Biopharm stands at a critical turning point where we must simultaneously target the present and the future through portfolio diversification," adding, "I hope all subsidiaries and departments will work together as one team to create even greater synergy in achieving our ultimate goals."

SK Biopharm continues to grow by establishing a direct sales system through its U.S. subsidiary, the first among Korean pharmaceutical companies. The company plans to accelerate its U.S. business growth by leveraging the strong performance of cenobamate and diversifying its product portfolio through its local sales network.

This content was produced with the assistance of AI translation services.